Compare Sanofi SA (SNY) vs Visa Inc (V) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Sanofi SA vs Visa Inc — how do they compare? Sanofi SA trades at $40.1 (market cap $95.18B), while Visa Inc trades at $374.08 (market cap $704.20B). The key difference: Visa Inc is far larger — about 7.4× Sanofi SA's market cap, and Sanofi SA pays the higher dividend (6.01%). Which is the better fit depends on your goals — on Pluang, investors hold Sanofi SA for 94 Days and Visa Inc for 115 Days on average.
| SNY | V | |
|---|---|---|
Market Cap | $95.18B | $704.20B |
Volume | 2,995,646 | 6,405,857 |
Sector | Health | Financials |
52-Week High | $52.34 | $384.14 |
52-Week Low | $39.51 | $295.52 |
Typical Hold Time | 94 Days | 115 Days |
Enterprise Value | $114.48B | $714.78B |
Dividend Yield | 6.01% | 0.71% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
SNY trades at $40.2, up 1.62% on the day, with a bearish technical signal from moving averages but a neutral oscillator stance. The company reported revenue of $46.72B in 2025 with a net income margin of 16.72%, and it has beaten EPS estimates for the last three quarters. Recent news highlights a significant $8B immunology alliance expansion with Regeneron, signaling strong pipeline development.
The outlook is mixed; analyst consensus leans hold (51.86%) with a buy rating at 44.44%, reflecting optimism on new drug launches but caution over future profit margin compression projected for 2026. Key risks include execution of the expanded Regeneron partnership and managing debt levels amid investing cash flow volatility.
Visa (V) trades at $372.10, up 0.39% with strong bullish technical momentum. The company demonstrates robust fundamentals with 2025 revenue of $40B and net income margin of 50.78%. Recent earnings beats and a consensus price target of $422.24 reflect Wall Street optimism. Visa's expansion into AI-powered commerce through Intelligent Commerce Connect positions it for future growth while maintaining exceptional profitability metrics including 61.79% ROE.
Visa presents a compelling investment case with consistent earnings outperformance and dominant market position. Key opportunities include AI integration and stablecoin partnerships, while risks involve regulatory scrutiny and fintech competition. With 85% analyst buy ratings and 13% upside to consensus target, the stock offers growth potential despite premium valuation multiples.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Sanofi SA
Sanofi develops and markets drugs with a concentration in oncology, immunology, cardiovascular disease, diabetes, and vaccines. However, the company's decision in late 2019 to pull back from the cardio-metabolic area will likely reduce the firm's footprint in this large therapeutic area. The company offers a diverse array of drugs with its highest revenue generator, Dupixent, representing just over 10% of total sales, but profits are shared with Regeneron. About 30% of total revenue comes from the United States and 25% from Europe. Emerging markets represent the majority of the remainder of revenue.
Read more on SNY →About Visa Inc
Visa Inc. operates a retail electronic payments network and manages global financial services. The Company also offers global commerce through the transfer of value and information among financial institutions, merchants, consumers, businesses, and government entities.
Read more on V →
